EZH2 inhibitors have demonstrated effectiveness in specific subtypes of pediatric AML overexpressing EZH2 [104], and in primary pediatric B-cell and T-cell ALL samples [105]. Here, EZH2 is linked to acute lymphoblastic leukemia.